MethylGene, Inc. is established in Canada and listed on the Canadian Exchange.
Charles Baum is appointed President & CEO. He was previously the SVP of Global Biotherapeutic Clinical Research for Pfizer, Inc.
Company relocated headquarters to San Diego and Mirati Therapeutics is created (Mirati loosely translated means “targeted” in Italian). Mirati is listed as MRTX on NASDAQ.
Phase 1/1b clinical trials of sitravatinib, a multi-kinase inhibitor asset that originated with MethylGene, begin and continue to advance.
Thought to be “undruggable”, data is published showing it’s possible to target the G12C protein. In 2014, Mirati & Array set out to create a successful molecule.
January 2019, first patient in Phase 1/2 clinical trial of MRTX849, a direct KRASG12C inhibitor, is dosed and shows first clinical data in October 2019.
SAPPHIRE trial kicks off mid-2019 and begins enrolling patients.
Early in 2020, KRASG12D inhibitor candidates advance into IND-enabling studies. The portfolio continues to advance and diversify as other preclinical assets in various solid tumors are evaluated.
KRAZATI is approved as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.